Patients referred for cardiac rehabilitation may derive benefit from combining trimetazidine with exercise training, because both treatments produce similar effects in the cardiovascular system. Patients with viable myocardium should, in theory, obtain the greatest benefit, because trimetazidine improves the contractility of dysfunctional hibernating/stunned myocardium, whereas exercise has the...

Trimetazidine is a piperazine-derived metabolic agent, which exerts cell protective effects and has been reported to be efficient in the treatment of chronic stable angina pectoris. In addition, it has been shown to exert protection against acute myocardial infarction. The present study aimed to investigate whether trimetazidine protects against cardiac ischemia/reperfusion (I/R) injury, and to...

Trimetazidine is a cytoprotective drug whose cardiovascular effectiveness, especially in patients with stable ischemic heart disease, has been the source of much controversy in recent years; some have gone so far as to treat the medication as a 'placebo drug' whose new side effects, such as Parkinsonian symptoms, outweigh its benefits. This article is an attempt to present the recent key studie...

It has recently been shown that trimetazidine, a 3-ketoacyl coenzyme A thiolase inhibitor, improves overall glucose metabolism in diabetic patients with left ventricular dysfunction. Forearm glucose and lipid metabolism and forearm release of endothelial vasodilator and vasoconstrictor factors during prolonged partial inhibition of fatty acid oxidation by trimetazidine have recently been evalua...

High rates of fatty acid oxidation in the heart and subsequent inhibition of glucose oxidation contributes to the severity of myocardial ischemia. These adverse effects of fatty acids can be overcome by stimulating glucose oxidation, either directly or secondary to an inhibition of fatty acid oxidation. We recently demonstrated that trimetazidine stimulates glucose oxidation in the heart second...

This article focuses on the management of concomitant angina in patients with heart failure, as described in the 2016 European guidelines for the diagnosis and treatment of acute and chronic heart failure. Trimetazidine has been included in this new guideline because it is considered an effective and safe antianginal treatment in patients with angina and heart failure. It is well-known that imp...

Trimetazidine is an effective anti-anginal agent and anti-ischaemic effect. The objective of this study was to assess the in vitro dissolution and to evaluate the bioavailability of two brands of trimetazidine dihydrochloride tablets. Prior to the in vivo PKs study, an in vitro comparative dissolution test was performed for 2 oral brands of trimetazidine dihydrochloride tablets (20 mg). In vivo...

Metabolic treatment involves the use of drugs that improve cardiomyocyte function. Trimetazidine (Vastarel1MR) is the most investigated drug in this group with a well-established role in the treatment of chronic angina. The available data suggest that therapy combining trimetazidine and hemodynamic drugs is effective in patients with chronic heart failure, leading to additional benefits such as...

Abstract Background Trimetazidine as adjunctive therapy in cardioischemic patients has shown improvement angina and left ventricular ejection fraction. Recent trials have conflicting evidence on its effect hard clinical outcomes. Purpose The objective of this meta-analysis is to compare the efficacy trimetazidine versus placebo reducing cardiac mortality major adverse events (MACE) coronary art...

BACKGROUND AND OBJECTIVE Trimetazidine has mainly been used in coronary insufficiency, angina and elderly myocardial infarction. However, the effect of trimetazidine on the efficacy, heart rate variability (HRV) and protection of myocardial ischemia in elderly patients with acute coronary syndrome (ACS) remains unclear. This study aimed to investigate the effect of trimetazidine on the efficacy...